IP Verse

Fresenius Kabi SwissBiosim, GmbH et al. vs Regeneron Pharmaceuticals, Inc. - IPR2025-01269

Explore the PTAB proceeding IPR2025-01269 filed by Fresenius Kabi SwissBiosim, GmbH et al. against Regeneron Pharmaceuticals, Inc. on Jul 14, 2025. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number: IPR2025-01269
Filing Date: Jul 14, 2025
Petitioner: Fresenius Kabi SwissBiosim, GmbH et al.
Respondent: Regeneron Pharmaceuticals, Inc.
Status: Pending
Respondent Application Number: 16159282
Respondent Tech Center: 1600
Respondent Patent Number: 10828345

Proceeding Decision New

Decision pending - set alert to receive updates

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.

Show Exhibit Documents

Document Name	Filing Date	Category	Filing Party
Alert me when new update on this case
Regeneron's Preliminary Patent Owner Response (IPR2025-01269)	Oct 24, 2025	PAPER	PATENT OWNER
U.S. Provisional Application No. 61/432,245	Oct 24, 2025	EXHIBIT	PATENT OWNER
U.S. Provisional Application No. 61/434,836	Oct 24, 2025	EXHIBIT	PATENT OWNER
U.S. Provisional Application No. 61/561,957	Oct 24, 2025	EXHIBIT	PATENT OWNER
Eylea Label (November 18, 2011)	Oct 24, 2025	EXHIBIT	PATENT OWNER
P.J. Rosenfeld et al., Ranibizumab for Neovascular Age Related Macular Degeneration, 355 N. ENG. J. MED. 1419 (2006)	Oct 24, 2025	EXHIBIT	PATENT OWNER
C.D. Regillo et al., Randomized, Double-Masked, ShamControlled Clinical Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 1, 145 AM. J. OPHTHALMOLOGY 145(2): 239-248 (2008)	Oct 24, 2025	EXHIBIT	PATENT OWNER
N. M. Bressler, Antiangiogenic Approaches to Age-Related Macular Degeneration Today, 116 AM. ACAD. OPHTHALMOLOGY S15 (2009)	Oct 24, 2025	EXHIBIT	PATENT OWNER
Curriculum Vitae of Dr. Neil M. Bressler, M.D.	Oct 24, 2025	EXHIBIT	PATENT OWNER
Expert Declaration of Dr. Neil M. Bressler in Support of Patent Owner Preliminary Response.	Oct 24, 2025	EXHIBIT	PATENT OWNER
MACUGEN® Prescribing Information (2006)	Oct 24, 2025	EXHIBIT	PATENT OWNER
SUSTAIN - Study of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (Dec. 09, 2010), https://www.clinicaltrials.gov/study/ NCT00331864?tab=history&a=10#version-content-panel	Oct 24, 2025	EXHIBIT	PATENT OWNER
A.P. Adamis, Angiogenesis and Ophthalmic Disease, 3 ANGIOGENESIS 9 (1999)	Oct 24, 2025	EXHIBIT	PATENT OWNER
G.L. Skuta et al, Retina And Vitreous 72-73, 109-114, 121, 128-29 (Section 12, 2009)	Oct 24, 2025	EXHIBIT	PATENT OWNER
Barbazetto et al., Dosing Regimen and the Frequency of Macular Hemorrhages in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab, 30 RETINA 1376 (2010).	Oct 24, 2025	EXHIBIT	PATENT OWNER
P.J. Patel et al., A Randomised, Double-Masked Phase III/IV Study of the Efficacy and Safety of Avastin® (Bevacizumab) Intravitreal Injections Compared to Standard Therapy in Subjects with Choroidal Neovascularization Secondary to Age-related Macular Degeneration: Clinical Trial Design, 9 BIOMED CENT. 56 (2008)	Oct 24, 2025	EXHIBIT	PATENT OWNER
Prospective OCT Study with Lucentis for Neovascular AMD (PrONTO study), NCT00344227, ClinicalTrials.gov (June 23, 2006), https://clinicaltrials.gov/study/ NCT00344227?tab=history&a=1#version-content-panel	Oct 24, 2025	EXHIBIT	PATENT OWNER
Petitioner's Opposition to Patent Owner's Request for Discretionary Denial	Oct 23, 2025	PAPER	PETITIONER
Ex. 1056	Oct 23, 2025	EXHIBIT	PETITIONER
Ex. 1057	Oct 23, 2025	EXHIBIT	PETITIONER
EX2001 - 16159282 File Certified - Part 1 of 6	Sep 23, 2025	EXHIBIT	PATENT OWNER
EX2001 - 16159282 File Certified - Part 2 of 6	Sep 23, 2025	EXHIBIT	PATENT OWNER
EX2001 - 16159282 File Certified - Part 3 of 6	Sep 23, 2025	EXHIBIT	PATENT OWNER
EX2001 - 16159282 File Certified - Part 4 of 6	Sep 23, 2025	EXHIBIT	PATENT OWNER
EX2001 - 16159282 File Certified - Part 5 of 6	Sep 23, 2025	EXHIBIT	PATENT OWNER
EX2001 - 16159282 File Certified - Part 6 of 6	Sep 23, 2025	EXHIBIT	PATENT OWNER
EX2002 - Compare Record History ver 9-10 2009-04-28 NCT00509795	Sep 23, 2025	EXHIBIT	PATENT OWNER
EX2003 - NCT-795 as submitted in App. No. 14-972,560	Sep 23, 2025	EXHIBIT	PATENT OWNER
EX2004 - Donald Trump Remarks Transcript October 7th	Sep 23, 2025	EXHIBIT	PATENT OWNER
EX2005 - Regeneron - the Company that Trump claims cured his Covid	Sep 23, 2025	EXHIBIT	PATENT OWNER
EX2006 - Trump calls coronavirus treatment he received a cure	Sep 23, 2025	EXHIBIT	PATENT OWNER
Patent Owner's Discretionary Denial Brief	Sep 23, 2025	PAPER	PATENT OWNER
Notice: Power of Attorney	Aug 4, 2025	PAPER	PATENT OWNER
Notice: Mandatory Notice	Aug 4, 2025	PAPER	PATENT OWNER
Notice: Notice filing date accorded	Jul 23, 2025	PAPER	BOARD
Petitioner Fresenius Kabi SwissBiosim, GmBh Power of Attorney	Jul 14, 2025	PAPER	PETITIONER
Fresenius Kabi SwissBiosim, GmBH Petition for IPR of USP10,828,345	Jul 14, 2025	PAPER	PETITIONER
Ex. 1001	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1002	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1003	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1004	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1005	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1006	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1007	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1008	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1009	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1010	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1011	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1012	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1013	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1014	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1015	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1016	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1017	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1018	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1019	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1020	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1021	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1022	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1023	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1024	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1025	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1026	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1027	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1028	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1029	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1031	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1032	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1033	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1034	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1035	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1036	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1037	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1038	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1039	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1040	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1041	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1042	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1043	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1044	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1045	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1046	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1047	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1048	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1049	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1050	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1051_Part 1	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1051_Part 2	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1052	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1053	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1054	Jul 14, 2025	EXHIBIT	PETITIONER
Ex. 1055	Jul 14, 2025	EXHIBIT	PETITIONER